Pharmafile Logo
Pharmafocus logo
Advanced Search

DMD

Showing 8 posts of 8 posts found.

Sarepta Therapeutics gains expanded FDA approval for DMD treatment

June 21, 2024
Medical Communications DMD, Musculo-skeletal disorder, Sarepta Therapeutics

Sarepta Therapeutics has announced that the US Food and Drug Administration (FDA) has approved an expansion to the labelled indication …

News

Pfizer shares update on DMD gene therapy clinical trial

June 13, 2024
Research and Development DMD, Musculo-skeletal disorder, Pfizer, duchenne muscular dystropy, gene therapy

Pfizer has announced an update from its phase 3 randomised, multicentre, double-blind, placebo-controlled CIFFREO trial, which assessed the investigational mini-dystrophin …

News

Santhera announces Early Access Program by partner Sperogenix for DMD treatment

June 11, 2024
Medical Communications DMD, Musculo-skeletal disorder, early access, muscular dystrophy, santhera

Santhera Pharmaceuticals has announced that its partner Sperogenix Therapeutics has launched a paid-for Early Access Program (EAP) for Agamree (vamorolone) …

News
5204602349_c87b204860_z

FDA turns down Sarepta’s DMD drug over safety concerns

August 20, 2019
Manufacturing and Production DMD, FDA, approval safety, pharma, sarepta

The FDA has declined to approve Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) drug, citing safety concerns including risk of infection …

News
golden_retriever

Breakthrough gene therapy shows promise in Duchenne muscular dystrophy

July 26, 2017
Research and Development DMD, Duchenne Muscular Dystrophy, University of London, University of Nantes, biotech, drugs, pharma, pharmaceutical

New research, led by teams from AFM-Telethon laboratory in Nantes and the University of London, have developed a gene therapy …

News
clinicaltrial1

US panel says Sarepta’s trial DMD drug not proven effective

April 26, 2016
Manufacturing and Production, Research and Development DMD, US FDA, drug trial, sarepta

A US advisory committee has concluded Sarepta Therapeutics’ (Nasdaq: SRPT) trial drug to treat muscle wasting condition has not proved …

News
drugs1

NICE recommends PTC Therapeutics’ Translarna to treat Duchenne muscular dystrophy

April 18, 2016
Sales and Marketing DMD, Duchenne Muscular Dystrophy, NICE, PTC Therapeutics, Translarna, regulation

Shares in drug maker PTC Therapeutics (Nasdaq: PTCT) jumped after the National Institute for Health and Care Excellence (NICE) backed …

News
Steve Bates image

UK life sciences gains £93 million backing

July 31, 2013
Research and Development, Sales and Marketing BIA, DMD, life sciences

The UK life sciences sector has been given a new £93.2 million package of support by the government to help …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026